Drug interactions
Saquinavir + Umeclidinium-vilanterol
Severity: Major
Saquinavir and Umeclidinium-vilanterol: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Saquinavir prolongs the QT interval and strongly inhibits CYP3A4, which raises vilanterol exposure. Together this increases the risk of tachycardia, hypokalemia and ventricular arrhythmia.
What this interaction means in plain words
Saquinavir and Umeclidinium-vilanterol can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
CYP3A4 inhibition raises vilanterol levels, combined with additive QT prolongation.
What to do
Avoid the combination where possible; saquinavir itself needs ECG assessment before use. If unavoidable, monitor ECG, potassium and cardiovascular adverse effects.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Saquinavir and Umeclidinium-vilanterol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Umeclidinium-vilanterol
Frequently asked questions
Can I take Saquinavir with Umeclidinium-vilanterol?
MediHelp rates the interaction as major. Saquinavir and Umeclidinium-vilanterol can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Saquinavir prolongs the QT interval and strongly inhibits CYP3A4, which raises vilanterol exposure. Together this increases the risk of tachycardia, hypokalemia and ventricular arrhythmia.
How serious is the interaction between Saquinavir and Umeclidinium-vilanterol?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where possible; saquinavir itself needs ECG assessment before use. If unavoidable, monitor ECG, potassium and cardiovascular adverse effects.
What other medicines interact with Umeclidinium-vilanterol?
MediHelp also lists interactions of Umeclidinium-vilanterol with, for example, Aclidinium, Amiodarone, Amitriptyline. The full list is on the Umeclidinium-vilanterol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
